David Pérol
0000-0002-6429-7419
Publication & Citation Trends
Publications
0 total
2693MO COTESARC: A multicentre, open-label, phase I-II evaluating the combination of MEK and PDL-1 inhibitors in patients with advanced soft tissue sarcoma (STS)
Cited by 0
Semantic Scholar
216eP MegaMOST - A multicenter, open-label, molecularly selected bayesian phase II platform trial in advanced or metastatic solid tumors: Final analysis of the trametinib cohort
Cited by 0
Semantic Scholar
IMMUNONET: A multicenter, open-label, proof-of-concept phase II trial evaluating NP137 as add-on therapy in advanced/metastatic solid tumors treated with standard immunotherapies.
Cited by 0
Semantic Scholar
587P Recent nationwide overall survival trends across subtypes in 33,044 patients with metastatic breast cancer in the French ESME cohort
Cited by 0
Semantic Scholar
Reply to Letter to the Editor "Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer" by Arenhardt and Nogueira-Rodrigues.
Cited by 1
Semantic Scholar
515P Real world treatment patterns and effectiveness after disease progression on CDK4/6 inhibitors for HR+/HER2- metastatic breast cancer in the ESME-MBC cohort
Cited by 0
Semantic Scholar
966P IMMUNONET: A proof of concept phase II evaluating NP137 as add on therapy in solid tumors under standard immunotherapies: Interim analysis of primary and secondary refractory cohorts
Cited by 0
Semantic Scholar
FIRST-NEC (GFPC 01-2022): A multicenter phase II study evaluating the efficacy and safety of the combination of durvalumab with etoposide and platinum as first line treatment in patients with advanced large-cell neuroendocrine lung carcinomas (LCNECs).
Cited by 0
Semantic Scholar
Research Topics
Cancer Genomics and Diagnostics
(60)
Sarcoma Diagnosis and Treatment
(57)
Lung Cancer Treatments and Mutations
(48)
Cancer Treatment and Pharmacology
(47)
Cancer Immunotherapy and Biomarkers
(43)
Affiliations
Université Claude Bernard Lyon 1
Centre National de la Recherche Scientifique
Inserm
Université de Lyon
Institut Gustave Roussy